<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03622203</url>
  </required_header>
  <id_info>
    <org_study_id>CHANCE</org_study_id>
    <nct_id>NCT03622203</nct_id>
  </id_info>
  <brief_title>Outcome of CHAllenging lesioNs and Patients Treated With Polymer Free Drug-CoatEd Stent</brief_title>
  <acronym>CHANCE</acronym>
  <official_title>Outcome of CHAllenging lesioNs and Patients Treated With Polymer Free Drug-CoatEd Stent (&quot;Biofreedom&quot;): the CHANCE a Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Città della Salute e della Scienza di Torino</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Città della Salute e della Scienza di Torino</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Length of DAT (Dual Antiplatelet therapy) represents one of the most challenging choices for
      interventional cardiologist.

      Prolonged DAT reduces risk of subsequent MI (Myocardial Infarction) with an increase in major
      bleedings, consequently with a neutral effect on survival [1].

      Recently a Polymer-free Drug-Coated coronary stent has been tested in a randomized controlled
      trial with only one month of DAT due to its peculiar features, with an increased efficacy
      compared to BMS (Bare Metal Stent) and with a not negligible risk of ST at one year (about
      2%)[2,3].

      The RCT despite its promising design (inclusion of high risk patients like those with
      previous bleeding or with severe renal disease) showed a major limitation, that is:

        1. patients who are often offered a Biofreedom in real life, that is those with active
           cancer or needing major surgery or on OAT (Oral Anticoagulation)

        2. and patients with bifurcation and multivessel disease, that is those with an increased
           risk of ST [4]

        3. STEMI patients [5] were underrepresented (less than 30%). Consequently we performed this
           multicenter study to evaluate safety and efficacy of Biofreedom in real life patients.

      POCE (a composite end point of death, myocardial infarction, target lesion revascularization)
      and DOCE (cardiac death, MI-TLR and TLR) will be the primary end points, while its single
      components will be the secondary ones along stent thrombosis and with bleedings (Barc
      classification).

      At least 12 months The Leaders FREE (2) reported an incidence of MACE of 9.4% at one year in
      overall patients. If there is a true difference in favour of the experimental treatment of
      1.2%, then 870 patients are required to be 80% sure that the upper limit of a one-sided 95%
      confidence interval (or equivalently a 90% two-sided confidence interval) will exclude a
      difference when compared to non selected patients of more than 2% [5]

      All patients implanting Biofreedom with these prespecified analysis:

        1. Clinical

             -  Diabetic patients (both insulin and not insulin depenent)

             -  Requiring oral anticoagulation

             -  On active cancer (that is requiring chemio or radio-therapy and or surgery)

             -  Requiring surgery

             -  STEMI

        2. Interventional

             -  Bifurcation (both provisional both 2 stents)

             -  Multivessel

             -  Ostial
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our interest is to test the performance of these stents in real life patients
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Actual">May 1, 2018</completion_date>
  <primary_completion_date type="Actual">January 31, 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Incidence of POCE (primary patient-oriented endpoint)</measure>
    <time_frame>At least 6 months</time_frame>
    <description>Incidence of POCE (a composite and mutual exclusive end point of death, myocardial infarction, target lesion revascularization)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Death</measure>
    <time_frame>At least 6 months</time_frame>
    <description>Incidence of Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Myocardial Infarction</measure>
    <time_frame>At least 6 months</time_frame>
    <description>Incidence of Myocardial Infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of TLR</measure>
    <time_frame>At least 6 months</time_frame>
    <description>Incidence of target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Cardiac Death</measure>
    <time_frame>At least 6 months</time_frame>
    <description>Incidence of Cardiac Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of MI-TLR</measure>
    <time_frame>At least 6 months</time_frame>
    <description>Incidence of Myocardia Infarction TLR</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">1000</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Drug Eluting Stent</condition>
  <condition>STEMI</condition>
  <arm_group>
    <arm_group_label>Real life patients</arm_group_label>
    <description>Patients who are often offered a Biofreedom in real life, that is those with active cancer or needing major surgery or on OAT (Oral Anticoagulation)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Difficult coronary lesions</arm_group_label>
    <description>Patients with bifurcation and multivessel disease, that is those with an increased risk of ST</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STEMI</arm_group_label>
    <description>Patients with STEMI</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Biofreedom</intervention_name>
    <description>Use of Biofreedom in real life patients</description>
    <arm_group_label>Difficult coronary lesions</arm_group_label>
    <arm_group_label>Real life patients</arm_group_label>
    <arm_group_label>STEMI</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients implanting Biofreedom with these prespecified analysis:

          1. Clinical

               -  Diabetic patients (both insulin and not insulin depenent)

               -  Requiring oral anticoagulation

               -  On active cancer (that is requiring chemio or radio-therapy and or surgery)

               -  Requiring surgery

               -  STEMI

          2. Interventional

               -  Bifurcation (both provisional both 2 stents)

               -  Multivessel

               -  Ostial
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical

               -  Diabetic patients (both insulin and not insulin depenent)

               -  Requiring oral anticoagulation

               -  On active cancer (that is requiring chemio or radio-therapy and or surgery)

               -  Requiring surgery

               -  STEMI

          2. Interventional

               -  Bifurcation (both provisional both 2 stents)

               -  Multivessel

               -  Ostial

        Exclusion

          1. clinical less than 18 years old or more than 80

          2. interventional last remaing vessel
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabrizio D'Ascenzo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Città della Salute e Della Scienza di Torino</affiliation>
  </overall_official>
  <reference>
    <citation>Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SL, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR Jr, Krucoff MW, Hermiller J, Dauerman HL, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014 Dec 4;371(23):2155-66. doi: 10.1056/NEJMoa1409312. Epub 2014 Nov 16.</citation>
    <PMID>25399658</PMID>
  </reference>
  <reference>
    <citation>Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrié D, Naber C, Lipiecki J, Richardt G, Iñiguez A, Brunel P, Valdes-Chavarri M, Garot P, Talwar S, Berland J, Abdellaoui M, Eberli F, Oldroyd K, Zambahari R, Gregson J, Greene S, Stoll HP, Morice MC; LEADERS FREE Investigators. Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. N Engl J Med. 2015 Nov 19;373(21):2038-47. doi: 10.1056/NEJMoa1503943. Epub 2015 Oct 14.</citation>
    <PMID>26466021</PMID>
  </reference>
  <reference>
    <citation>Garot P, Morice MC, Tresukosol D, Pocock SJ, Meredith IT, Abizaid A, Carrié D, Naber C, Iñiguez A, Talwar S, Menown IBA, Christiansen EH, Gregson J, Copt S, Hovasse T, Lurz P, Maillard L, Krackhardt F, Ong P, Byrne J, Redwood S, Windhövel U, Greene S, Stoll HP, Urban P; LEADERS FREE Investigators. 2-Year Outcomes of High Bleeding Risk Patients After Polymer-Free Drug-Coated Stents. J Am Coll Cardiol. 2017 Jan 17;69(2):162-171. doi: 10.1016/j.jacc.2016.10.009. Epub 2016 Oct 30.</citation>
    <PMID>27806919</PMID>
  </reference>
  <reference>
    <citation>D'Ascenzo F, Bollati M, Clementi F, Castagno D, Lagerqvist B, de la Torre Hernandez JM, ten Berg JM, Brodie BR, Urban P, Jensen LO, Sardi G, Waksman R, Lasala JM, Schulz S, Stone GW, Airoldi F, Colombo A, Lemesle G, Applegate RJ, Buonamici P, Kirtane AJ, Undas A, Sheiban I, Gaita F, Sangiorgi G, Modena MG, Frati G, Biondi-Zoccai G. Incidence and predictors of coronary stent thrombosis: evidence from an international collaborative meta-analysis including 30 studies, 221,066 patients, and 4276 thromboses. Int J Cardiol. 2013 Jul 31;167(2):575-84. doi: 10.1016/j.ijcard.2012.01.080. Epub 2012 Feb 22.</citation>
    <PMID>22360945</PMID>
  </reference>
  <reference>
    <citation>Naber CK, Urban P, Ong PJ, Valdes-Chavarri M, Abizaid AA, Pocock SJ, Fabbiocchi F, Dubois C, Copt S, Greene S, Morice MC; LEADERS FREE Investigators. Biolimus-A9 polymer-free coated stent in high bleeding risk patients with acute coronary syndrome: a Leaders Free ACS sub-study. Eur Heart J. 2017 Apr 1;38(13):961-969. doi: 10.1093/eurheartj/ehw203.</citation>
    <PMID>27190095</PMID>
  </reference>
  <reference>
    <citation>Blackwelder WC. &quot;Proving the null hypothesis&quot; in clinical trials. Control Clin Trials. 1982 Dec;3(4):345-53.</citation>
    <PMID>7160191</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>May 18, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2018</study_first_posted>
  <last_update_submitted>August 7, 2018</last_update_submitted>
  <last_update_submitted_qc>August 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Città della Salute e della Scienza di Torino</investigator_affiliation>
    <investigator_full_name>Fabrizio D'Ascenzo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

